Effect of policosanol on platelet aggregation in healthy volunteers

International Journal of Clinical Pharmacology Research

Volumn 16, Issue 2-3, 1996, Pages 67-72

  Valdes, S ^a   Arruzazabala, M L ^a   Fernandez, L ^a   Mas, R ^a   Carbajal, D ^a   Aleman, C ^a   Molina, V ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; POLICOSANOL;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

ADULT; BLOOD COAGULATION TESTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 0030512730     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arruzazabala M.L. et al. Cholesterol-lowering effects of policosanol in rabbits. Biology Res., 27, 205, 1994.
2. Rodriguez-Echenique C., Mesa R., Más R., Amor A., y Castaño G. Estudio del efecto sobre lipidos y lipoproteines séricas y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos Macaca arctoides. Arch. Venezolanos de Famnacologia y Terapeútica, 11, 74-79, 1992.
3. Hernández F. et al. Effect of Ateromixol (policosanol) on serum lipids and lipoproteins in healthy volunteers. Curr. Ther. Res., 51, 568-75, 1992.
4. Pons P. et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia, Curr, Ther, Res., 52, 507-13, 1992
5. Pons P. et al. Effects of policosanol in elderly hypercholesterolemic patients. Curr. Ther. Res., 53, 265-69, 1993
6. Illnait J. et al. Efectos del Ateromixol (PPG) sobre la hiperlipoproteinemia del tipo II. Rev. CENIC Cienci as Biológicas, 22, 74-76, 1991.
7. Castaño G. et al. Efectos del tratamiento con Ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM, 5, 21-28, 1991.
8. Solterol., Fuenmayor I., Colmenares J. Estudio comparative doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipoproteinemia tipo II. Arch. Venezolanes Farmac. y Terap., 12, 71-76, 1993.
9. Pons P. et al. Effects of policosanol successive dose increases on lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Clin. Pharmacol. Res., XIV, 27-33, 1994.
10. Bradlow B.A., Chetty N., Birnbaum M., Baker S.G., Settel H.C. Patelet function in familial hypercholesterolemia in South Africa and the effect of probucol. Thromb. Res., 26, 91-99, 1982.
11. Carvalho A.C.A. Colman R.W., Lees R.S. Platelet function in hyperlipoproteinemia. N. Engl. J. Med., 290, 434-38, 1974.
12. Colman R.W. Platelet function in hyperbetalipoproteinemia. Thromb Haemost., 39, 284-93, 1978.
13. 2 formation in type IIa hyperlipoproteinaemic patients. Eur. J. Clin. Invest., 14, 329-33, 1984
14. Viener A., Aviram M., Brook J.G. Abnormal plasma lipo-protein composition in hypercholesterolemic patients induces platelet activation. Eur. J. Clin. Invest., 14, 207-13, 1984.
15. Kramer R.M., Jakubowski J.A., Vaillancourt R., Deykin D. Effect of membrane cholesterol on phospholipid metabolism in thrombin-stimulated platelets. J. Biol. Chem., 257, 6844-849, 1982.
16. Bizos R., Wong L.K., Vaillancourt R., Lees R.S., Carvalho A.C. Platelet prostaglandin endoperoxide formation in hyperlipidemia. Thromb. Haemost., 38, 228, 1977.
17. 2 formation in platelets from patients affected by hyperlipo-proteinemia. Thromb Res., 50, 593-604, 1988.
18. Tremoli E., Maderna P., Sirtori M., Sirtori C.R. Platelet aggregation and malondialdehyde formation in type IIa hypercholesterolemic patients. Haemostasis, 8, 47-53, 1979.
19. Tremoli E., Folco G., Agradi E., Galli C. Platelet thromboxane and serum cholesterol. Lancet, i, 106-107, 1979.
20. Arruzazabala M.L., Carbajal D., Mas R., Garcia M., Fraga V. Effects of policosanol on platelet aggregation in rats. Throm-bosis Res., 69, 321, 1993.
21. 2. Prostaglandins Leuk. Essen. Fatty Acids, 49, 695, 1993.
22. Menéndez R. et al. Niveles plasmáticos y excretión de la radiactividad en voluntaries sanos tras la administración oral de octacosanol 3H. Rev. CENIC Cienc. Biol., 23, 1-2, 1992.
23. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond.), 194, 927, 1962.
24. Tofler G.H. et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N. Engl. J. Med., 316, 1514-1518, 1987.
25. Gotto A.M. AHA conference report on cholesterol. Circulation, 80, 717-48, 1989.
26. Briones E.R., Steiger D., Palumbo P.J., Kottke B.A., Primary hypercholesterolemia: Effect of treatment on serum lipids, lipo-protein fractions, cholesterol absorption, sterol balance and platelet aggregation. Mayo Clin. Proc., 59, 251-57, 1984.
27. Zucker M.L. et al. Platelet function in hypercholesterolaemics before and after hypolipidemic drug therapy. Haemostasis, 16, 57-64, 1986.
28. Sirtori M. et al. Clofibrate and tiadenol treatment in hyperlipoproteinemias: A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis. Atherosclerosis, 49, 149-61, 1983.
29. Schror K., Lobel P., Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids, 2, 67-73, 1990.
30. DiMinno G. et al. Increased fibrinogen binding to platelets from patients with familiar hypercholesterolemia. Aterosclerosis, 6, 203-211, 1986.
31. Banga J.D., Sixma J.J. Diabetes mellitus, vascular disease and thrombosis. Clin. Haematol., 15, 465-92, 1986.